ArticlePharmacogenomics2024

The cost-effectiveness of zolbetuximab in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma.

Shufei Lai et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.